AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1226582
Drug: VK744 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VK744 (300 mg TID for 2 days before, 5 days during, 3 days after saturation dive)
Trial: 21512889
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation [1.5 g/d n‐3 LCPUFA]
Trial: 23079140
Drug: Palatal implant
RxNorm normalized name: malate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatal implant (PI) supported anchorage
Trial: 12362799
Drug: Iron solution
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron solution plus ascorbic acid added to domestic drinking water
Trial: 7979623
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B in traditional incremental dose regimen (0.05, 0.10, 0.25, 0.50 and 1.0 mg/kg body weight on days 1, 2, 3, 4, and > 4)
Trial: 7979623
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B at a constant 1 mg/kg bodyweight per day from day 1
Trial: 7979623
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimens (incremental and constant dose)
Trial: 10070911
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron treatment
Trial: 1192712
Drug: Frusemide 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 120 nmol (40 mg) administered intravenously
Trial: 1192712
Drug: Frusemide 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 60 nmol (20 mg) administered intravenously
Trial: 24761394
Drug: Symbicort 80/4.5
RxNorm normalized name: Symbicort 80/4.5 Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort 80/4.5 mg/inhalation, two puffs twice daily
Trial: 24761394
Drug: Symbicort 160/4.5
RxNorm normalized name: Symbicort 160/4.5 Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort 160/4.5 mg/inhalation, two puffs twice daily
Trial: 24761394
Drug: Pulmicort 180
RxNorm normalized name: Pulmicort
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort 180 mcg/inhalation, two puffs twice daily
Trial: 23720894
Drug: Mw vaccine
RxNorm normalized name: polyethyloxazoline (200000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mw vaccine plus MDT
Trial: 18697469
Drug: 1-month depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month depot (Zoladex 3.6 mg)
Trial: 18697469
Drug: 3-month depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month depot (Zoladex LA 10.8 mg)
Trial: 16032972
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available preparation (reference)
Trial: 7565948
Drug: cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisapride (10 mg three times a day)
Trial: 7565948
Drug: ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (150 mg three times a day)
Trial: 7565948
Drug: omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole (20 mg per day)
Trial: 7565948
Drug: ranitidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine plus cisapride (10 mg three times a day)
Trial: 540455
Drug: metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (100 mg twice daily)
Trial: 25831670
Drug: 5ml of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml of 2% lidocaine intrauterine (Group L)
Trial: 25831670
Drug: 5ml of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml of 2% lidocaine intrauterine + 50mg of rectal diclofenac sodium (Group LD)
Trial: 23885143
Drug: Active Dietary
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Dietary Intervention (ADI) - 175 mg milk thistle extract, 20 mg secoisolariciresinol, 750 mg oat fiber extract, administered twice a day for 60 days
Trial: 21484280
Drug: Community-based STI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based STI treatment and counseling
Trial: 19661116
Drug: Renal dysfunction
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal dysfunction (eGFR <60 mL/min/1.73 m²)
Trial: 19661116
Drug: Worsening renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worsening renal function (decrease of eGFR of at least 15 mL/min/1.73 m² within 1 year)
Trial: 17227997
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (750 mg/day), Vitamin E (600 mg/day), and Beta-carotene (18 mg/day)
Trial: 12872340
Drug: Fulvestrant 250
RxNorm normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulvestrant 250 mg monthly
Trial: 10972174
Drug: Bovine immunoglobulin
RxNorm normalized name: Bovine immunoglobulin concentrate, cryptosporidium parvum
DrugBank: Cryptosporidium immune globulin (DB17785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine immunoglobulin milk concentrate (BIC) 20 g daily for 4 days
Trial: 8730344
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (CCBs), n = 14
Trial: 8730344
Drug: ACE inhibitors,
RxNorm normalized name: ACE INHIBITORS, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors, n = 12
Trial: 4054203
Drug: Nisoldipine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine, 10 mg
Trial: 4054203
Drug: Nifedipine, 20
RxNorm normalized name: Nifedipine, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 20 mg retard
Trial: 31728025
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy arm
Trial: 31728025
Drug: Dose-dense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense treatment arm
Trial: 18626830
Drug: Early abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early abciximab administration before transfer to the catheterisation laboratory (27 patients)
Trial: 18626830
Drug: Late abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late abciximab administration in the catheterisation laboratory just before pPCI (32 patients)
Trial: 15886988
Drug: Rigid gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigid gold implants
Trial: 9806046
Drug: RTS,S malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S malaria vaccine (vaccine 3)
Trial: 23962071
Drug: RTS,S malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S malaria vaccine
Trial: 7644924
Drug: Paclitaxel (135-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135-225 mg/m2) and Carboplatin (250-400 mg/m2)
Trial: 2654758
Drug: L-carnitine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine therapy (2 g twice daily for 45 weeks)
Trial: 321198
Drug: Mesoridazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoridazine (10 mg tablets)
Trial: 29577365
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oleuropein
Trial: 26758035
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy (IG)
Trial: 24967345
Drug: NeReBot robotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeReBot robotic therapy
Trial: 24967345
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapy
Trial: 22397784
Drug: Tadalafil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (10 mg nightly) with standard treatment of BPH
Trial: 22397784
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of BPH (placebo group)
Trial: 18063874
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L-AmB) prophylaxis
Trial: 15240596
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing regimen (ID) starting at 0.2 mg/d, increased by 0.2 mg/d increments to a maximum of 0.8 mg/d
Trial: 15240596
Drug: Fixed body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed body weight-based dosing regimen (FD) with sequential doses of 4, 8, and 12 microg/kg.d GH
Trial: 8317646
Drug: 10% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lignocaine gel with absorption promoter
Trial: 357073
Drug: 5 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Trial: 357073
Drug: 10 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Trial: 357073
Drug: 25 consecutive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Trial: 30668660
Drug: Buccal miniscrews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal miniscrews
Trial: 27541067
Drug: Auricular acupressure
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupressure therapy applied on acupoints (Jagung, Sinmun, Gyogam, Naebunbi) for 3 days during periods of extreme primary dysmenorrhea.
Trial: 24656425
Drug: Artemether (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether (80 mg once per day during the second week and fourth week)
Trial: 14609531
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical looking capsules)
Trial: 19440077
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (36, 54, 72, 90, or 108 mg/d)
Trial: 11642642
Drug: Combined spa-exercise
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spa-exercise therapy (3 weeks duration) including group physical exercises, walking, correction therapy, hydrotherapy, sports, and sauna visits.
Trial: 11642642
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual drug treatment and weekly group physical therapy).
Trial: 2492232
Drug: Depot leuprolide
RxNorm normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot leuprolide acetate (LA) 3.75 mg IM every 4 weeks for 24 weeks (Group A)
Trial: 2492232
Drug: IM placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM placebo with the same injection schedule (Group B)
Trial: 4338548
Drug: Simultaneous alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous alpha and beta receptor blockade
Trial: 27181910
Drug: Teneligliptin 5
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 5 to 40 mg once daily for 24 weeks
Trial: 27181910
Drug: Teneligliptin 20
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 20 mg once daily during 28-week open label extension
Trial: 24838155
Drug: Saxagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (5 mg once daily)
Trial: 20144258
Drug: Rooibos tea
RxNorm normalized name: SODIUM FLUORIDE 0.2 mg in 1 mL ORAL LIQUID [Hoo Gargle Rooibos Tea Flavor]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rooibos tea (400 ml)
Trial: 20144258
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (400 ml)
Trial: 1732429
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of high-dose recombinant interleukin-2 (rIL-2) three times daily
Trial: 1732429
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of high-dose recombinant interleukin-2 (rIL-2) 24-hour infusion
Trial: 6396239
Drug: Hydrochlorothiazide-amiloride combination
RxNorm normalized name: amiloride / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide-amiloride combination
Trial: 12001821
Drug: Tolterodine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 5 mg
Trial: 28300854
Drug: Oxybutynin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 7.5 mg
Trial: 7795832
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of weight loss and sodium restriction
Trial: 1737537
Drug: Topical 0.075%
RxNorm normalized name: capsaicin topical 0.075% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.075% capsaicin cream
Trial: 24577921
Drug: Ocucure (Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocucure (Test drug) 500mg, two tablets twice daily for 6-8 weeks
Trial: 24577921
Drug: Leutivit (Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leutivit (Control drug) 250mg, two tablets twice daily for 6-8 weeks
Trial: 24577921
Drug: Ocucure (Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocucure (Test drug)
Trial: 9695216
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 6 months)
Trial: 9695216
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide pulses (20 mg/kg/monthly for at least 6 pulses) combined with oral prednisolone (40-60 mg/day for 1.5 months with tapering)
Trial: 30063470
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide pulses
Trial: 1864449
Drug: 4% indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% indomethacin spray
Trial: 26915677
Drug: Idelalisib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib (100 mg twice daily)
Trial: 15863638
Drug: Nasal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal continuous positive airway pressure treatment
Trial: 30156211
Drug: Periarticular multimodal
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular multimodal drug injection (200 mg ropivacaine, 30 mg ketorolac tromethamine, 0.3 mg epinephrine, 5 mg hexadecadrol)
Trial: 26857465
Drug: 15 mL
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL water swallow
Trial: 25381136
Drug: Eribulin (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin (1.4 mg/m2 on days 1 and 8 every 21 days)
Trial: 25381136
Drug: Control (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (treatment of physician’s choice or capecitabine 1.25 g/m2 b.i.d. on days 1–14 every 21 days)
Trial: 10228288
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course indomethacin (0.2 to 0.1 to 0.1 mg/kg in 24 hours, n = 31)
Trial: 10228288
Drug: Long course
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long course indomethacin (0.1 mg/kg every 24 hours for 7 times, n = 30)
Trial: 1321893
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and radiotherapy (RT) including cisplatin 100 mg/m2 on days 1 and 29, vinblastine 3 mg/m2 on days 1, 3, 29, and 31, fluorouracil (5-FU) 30 mg/kg/d by infusion on days 1 to 3 and 29 to 31, and RT of 3,000 cGy in 15 fractions.
Trial: 1321893
Drug: Surgical resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical resection following neoadjuvant treatment.
Trial: 1321893
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy and RT followed by additional chemotherapy and RT after surgery.
Trial: 21038652
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with BG, BP, BL controlling and vitamin E administration (Group C)
Trial: 21038652
Drug: Group with
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group with BG, BP, BL controlling and DSP administration (Group D)
Trial: 17992056
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy and physical therapy
Trial: 799986
Drug: Tofranil 25
RxNorm normalized name: Tofranil 25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofranil 25 mg three times daily
Trial: 30284349
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide (up to 14 mg)
Trial: 20923251
Drug: DHEP/heparin plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP/heparin plaster
Trial: 15941146
Drug: Nebivolol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (1.25 to 5 mg per day)
Trial: 15941146
Drug: Betalok ZOK
RxNorm normalized name: Zokinvy
DrugBank: Lonafarnib (DB06448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betalok ZOK (12.5 to 100 mg per day)
Trial: 12817904
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg lithium
Trial: 22262484
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion
Trial: 6812750
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 9 g/l)
Trial: 30118528
Drug: Platform-switching implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switching implant (PS)
Trial: 30118528
Drug: Platform-switching implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switching implant and bone graft (BG/PS)
Trial: 30118528
Drug: Non-platform-switching implant
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platform-switching implant (Non-PS)
Trial: 30118528
Drug: Non-platform-switching implant
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platform-switching implant and bone graft (BG/Non-PS)
Trial: 30118528
Drug: Platform-switching implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switching implant (PS) and bone graft (BG/PS)
Trial: 27614801
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d omega-3 fatty acid supplementation
Trial: 17418112
Drug: Familiar solution
RxNorm normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Familiar solution (non-optimal solution)
Trial: 15866569
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (600 microg of busereline acetate per day starting in the midluteal phase of the cycle)
Trial: 15866569
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (0.25 mg/d of Cetrorelix starting from day 6 of the cycle)
Trial: 18411913
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone replacement therapy (HRT)
Trial: 1907128
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (NO RT)
Trial: 30157532
Drug: Liraglutide (≤1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (≤1.8 mg daily)
Trial: 26429360
Drug: High-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexmedetomidine (loading dose, 1 μg/kg; maintenance dose, 0.6 μg/kg/h)
Trial: 26429360
Drug: Low-dose dexmedetomidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexmedetomidine (loading dose, 0.6 μg/kg; maintenance dose, 0.3 μg/kg/h)
Trial: 26429360
Drug: High-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexmedetomidine
Trial: 12744870
Drug: CF‐BS‐ETEC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF‐BS‐ETEC vaccine
Trial: 7755164
Drug: β-lactam/β-lactamase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactam/β-lactamase inhibitor agents (ampicillin/sulbactam, ticarcillin/clavulanate, piperacillin/tazobactam)